Abscorbic acid commonly known as Vitamin C is a water-soluble vitamin, which is necessary in the body to form collagen in bones, cartilage, muscle, and blood vessels and aids in the absorption of iron. Dietary sources of vitamin C include fruits and vegetables, particularly citrus fruits such as oranges.
Severe deficiency of vitamin C causes scurvy. Although rare, scurvy includes potentially severe consequences, and can cause sudden death. Patients with scurvy are treated with vitamin C and should be under medical supervision.
Many uses for vitamin C have been proposed, but few have been found to be beneficial in scientific studies. In particular, research in asthma, cancer, and diabetes remains inconclusive, and no benefits have been found in the prevention of cataracts or heart disease.
Salix Pharmaceuticals, Ltd. today announced financial and operating results for the first quarter ended March 31, 2012 and other business updates.
They look like fruit, and indeed the nanoscale stars of new research at Rice University have tasty implications for medical imaging and chemical sensing.
Salix Pharmaceuticals, Ltd. today announced financial and operating results for the third quarter ended September 30, 2011 and other business updates.
Progenics Pharmaceuticals, Inc. and Salix Pharmaceuticals, Ltd. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing a supplemental New Drug Application (sNDA) for RELISTOR Subcutaneous Injection to treat opioid-induced constipation (OIC) in patients with non-cancer pain.
Salix Pharmaceuticals, Ltd. today announced findings from two analyses of a Phase 3 open-label study of RELISTOR (methylnaltrexone bromide) presented at the 30th Annual Scientific Meeting of the American Pain Society. The meeting is being held in Austin, TX, on May 19-21, 2011.
It would appear that in terms of composition, the intestinal bacteria of every individual can be divided into three main groups known as enterotypes. The intestinal bacteria in each enterotype organise themselves into distinct, stable clusters displaying common features.
Salix Pharmaceuticals, Ltd. today announced that the U.S. Patent and Trademark Office has issued three patents relating to rifaximin.
Salix Pharmaceuticals, Ltd. today announced that as of March 31, 2011 Lupin Ltd. granted Salix exclusive worldwide rights (except for India) to exploit Lupin technology and technology jointly developed by Lupin and Salix for all rifaximin products for human use. This agreement expands the collaboration that Salix and Lupin entered into as of September 30, 2009.
Salix Pharmaceuticals, Ltd. today announced that based on a telephone conversation with the U.S. Food and Drug Administration held last evening, the Company anticipates receiving a Complete Response Letter on or before the March 7, 2011 PDUFA goal date for the supplemental New Drug Application for XIFAXAN 550 mg tablets for the proposed indication of treatment of non-constipation irritable bowel syndrome and IBS-related bloating.
A study conducted at the University of Granada and at the University Hospital San Cecilio revealed that preterm mothers' milk contains low concentrations of coenzyme Q10. This is a complex of great medical importance, due both to its antioxidant capacity and to its role as a component of the electron transport chain, among other functions.
Salix Pharmaceuticals, Ltd. today announced the New England Journal of Medicine has published results from TARGET 1 and TARGET 2, the Company's two pivotal Phase 3 efficacy and safety studies of XIFAXAN (rifaximin) 550 mg tablets for the treatment of Irritable Bowel Syndrome without constipation, or Non-C IBS.
Salix Pharmaceuticals, Inc. today announced that the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2010) will be an important venue for ongoing discussion of hepatic encephalopathy, or HE.
Salix Pharmaceuticals, Ltd. today announced the presentation of two analyses of data from its Phase 3 pivotal clinical trials, TARGET 1 and 2, demonstrating a 14-day course of XIFAXAN 550 mg (rifaximin) taken three times daily achieved adequate relief of symptoms of non-constipation irritable bowel syndrome (non-C IBS) in a significantly greater proportion of patients compared with placebo.
Salix Pharmaceuticals, Ltd. today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Company's efficacy supplement to the New Drug Application (NDA) for XIFAXAN® (rifaximin) 550 mg tablets for the proposed indication of treatment of non-constipation irritable bowel syndrome (Non-C IBS) and IBS-related bloating.
A new study from researchers in Italy has found that a split-dosage schedule of bowel (colon) preparation is the most effective method for bowel cleansing before colonoscopy. Colonoscopies performed within six to eight hours of the end of preparation were associated with significantly better cleansing than those performed more than eight hours after the end of preparation. Two different types of bowel cleansing products were also assessed and researchers found that low-volume polyethylene glycol (PEG) plus ascorbic acid was as effective as high-volume PEG-electrolyte solution, but has superior palatability (or taste). This is the first study to demonstrate that the advantage of split-dosage intake is also true for low-volume bowel cleansing solutions.
Bayer's CONTOUR® USB meter, the first blood glucose monitor with unique plug & play diabetes management software, today received a silver Medical Design Excellence Award (MDEA). The MDEA recognizes excellence in medical product design and manufacturing. The independent judges for the prestigious award, sponsored by the specialist journal Medical Device and Diagnostic Industry, acknowledged the great innovative power and particularly user-friendly operation of Bayer's CONTOUR USB meter.
Salix Pharmaceuticals, Ltd. today announced that the Company has submitted an efficacy supplement to NDA 21-361 for XIFAXAN® (rifaximin) 550 mg tablets for the proposed indication of treatment of non-constipation irritable bowel syndrome (Non-C IBS) and IBS-related bloating.
Salix Pharmaceuticals, Ltd. today announced the availability of Xifaxan (rifaximin) 550 mg tablets for the reduction in risk of overt hepatic encephalopathy recurrence in patients 18 years of age or older. Those HE patients may now fill their Xifaxan 550 mg prescriptions in U.S. pharmacies and should speak with their doctors about this important treatment option.
Salix Pharmaceuticals, Ltd. today announced the Food and Drug Administration (FDA) has issued a complete response letter regarding the New Drug Application (NDA) for GIAZO™ (balsalazide disodium) Tablets 1.1 g. for the treatment of mild-to-moderate active ulcerative colitis in patients 18 years and older.
Salix Pharmaceuticals, Ltd. today announced plans for the Hepatic Encephalopathy Living Program (H.E.L.P.). H.E.L.P. is a first-of-its-kind patient and health care provider support program for the management of hepatic encephalopathy (HE) and will launch on May 24, 2010. The program will provide patients with HE educational materials, co-pay assistance, treatment adherence support and a 24-hour toll-free hotline.